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of ivabradine plus standard therapy being cost-effective at a threshold of € 36,000/
QALY was found to be 96% in both within trial and lifetime analysis. This result is 
driven by a reduction in mortality and hospitalisations and the associated costs of 
care. ConClusions: Ivabradine added to standard care could be a cost-effective 
treatment for the treatment in CHF patients in Greece.
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With 7 million deaths per year, ischaemic heart disease is the leading cause 
of mortality worldwide. In Acute Coronary Syndrome (ACS), the vast majority 
of fatal cardiovascular events occur after hospital discharge. Guidelines recom-
mend antithrombotic treatment for secondary prevention after ACS. objeCtives: 
To assess the cost-effectiveness of rivaroxaban 2.5mg BID in combination with 
standard antiplatelet therapy (ASA alone or in combination with a thienopyri-
dine [clopidogrel or ticlopidine]) versus standard antiplatelet therapy alone for 
prevention of secondary events in ACS patients from a Swedish societal perspec-
tive. Methods: A Markov model is used to capture single and multiple events, 
costs and utilities based on the time since index event to reflect clinical practice. 
For the first 2 years the model uses data from the ATLAS ACS 2-TIMI 51 clinical 
trial including efficacy, safety, treatment discontinuation and average patient 
age. After 2 years, transition probabilities were extrapolated using an exponen-
tial function method. Estimates for life expectancy, drug acquisition costs and 
other medical and indirect costs were derived from published Swedish sources. 
Cost and effects are discounted at 3.0%. Univariate and probabilistic sensitivity 
analyses were conducted with an assumed willingness to pay (WTP) threshold of 
SEK 500,000. Results: For the base case scenario, incremental life time costs are 
estimated at SEK 10,000.44 (€ 1,156), incremental QALYs at 0.14, and incremental 
cost per QALY at SEK 71,245.76 (€ 8,236). Univariate sensitivity analyses indicate 
that the results are sensitive to changes in the cost of rivaroxaban and baseline 
utility value. At an assumed WTP of SEK 500,000, rivaroxaban in combination with 
standard antiplatelet therapy is expected to be cost-effective. ConClusions: 
From a Swedish societal perspective, secondary prevention with rivaroxaban 
2.5mg BID in combination with standard antiplatelet therapy can be considered 
a cost-effective option for patients with ACS. Sensitivity analyses demonstrated 
that the results are robust.
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objeCtives: The most common cardiac arrhythmia (atrial fibrillation, AF) 
increases the risk of morbidity and mortality. We estimated the health and eco-
nomic consequences of the use of apixaban compared with warfarin reducing the 
risk of stroke in patients with AF, from the perspective of the Instituto Mexicano 
del Seguro Social (IMSS). Methods: We performed a cost-effectiveness analysis 
using a Markov model (17 health states, six-week cycles), which simulates patients 
treated with warfarin (fixed dose: 5mg/day) or apixaban (10mg/day). Patients enter 
the model at age 70 and remain there until death (disease-related or according to 
Mexican life tables). Safety, efficacy and utilities were extracted from published 
sources. The costs of warfarin and AF-related clinical events were extracted from 
IMSS sources. The cost of apixaban was provided by the manufacturer. Costs are 
expressed in US$, 2013 and a 5% per-year discount rate was applied. Years of 
life and quality adjusted life years (QALYs) gained were the health outcomes. 
Univariate and probabilistic sensitivity analyzes were performed. Results: The 
model estimated 7.645 life years and 5.454 QALYs in the apixaban arm, which 
means 0.147 and 0.160 gained life years and QALY’s, respectively (regarding war-
farin). The costs of apixaban and warfarin were US$14,943 and US$15,042, respec-
tively (apixaban is a dominant alternative). Health gains with apixaban are driven 
by fewer event-related deaths (10/1000 patients at risk) as well as fewer hemor-
rhagic strokes (12) and bleeding (13 major bleeds, 41 clinically non-major bleeds) 
compared to warfarin-treated patients. Treatment costs are driven by drug acqui-
sition cost (apixaban) and monitoring cost (warfarin). ConClusions: Apixaban 
is more effective and safer than warfarin reducing the risk of stroke associated 
with AF, as well as bleeding events. To achieve this improvement, no additional 
economic resources need to be invested, which makes apixaban a cost-saving 
intervention in the context of the IMSS.
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objeCtives: Apixaban is an oral anticoagulant that has demonstrated a supe-
rior clinical profile compared to warfarin and aspirin in the management of 
patients with non-valvular Atrial Fibrilation (NVAF) and at least one additional 
risk factor for stroke. The objective of the present analysis was to assess the 
cost-effectiveness of apixaban against warfarin and aspirin for the preven-
tion of stroke in patients with NVAF in Greece. Methods: A Markov model 
that evaluated clinical events, quality adjusted life expectancy and costs for 
patients treated with apixaban and warfarin or aspirin (VKA-suitable and 
Henriksson reported that surgery plus medical management can be considered 
cost effective as a treatment of asymptomatic carotid stenosis in 65 year-old men. 
He assumed a surgery relative risk reduction of 65.5%, or approximately an abso-
lute risk reduction (ARR) of 8% in this population. However, data for the compara-
tor arm (medical management alone) were dated and did not reflect efficacies 
of current medical therapies. objeCtives: To analyze using Bayesian methods, 
asymptomatic carotid stenosis clinical trial data, and more current medical therapy 
data the probability of achieving this 8% ARR and an incremental cost per QALY 
of approximately $50,000 (US, inflated - 2013 dollars). Methods: The outcome of 
interest from the clinical trials was the mean difference in the probability of any 
stroke or perioperative death between surgery (carotid endarterectomy [CEA]) and 
aggressive medical management (MM). The CEA data came from the Asymptomatic 
Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial 
(ACST). The updated medical management data came from a systematic review 
published in the journal Stroke (Abbott, 2009). The Bayesian analysis employed a 
Beta-Binomial Model. Results: The posterior distribution of the Bayesian analysis 
representing the ARR of CEA versus MM had a mean of 0.008 with an essentially 
zero probability of achieving the Henriksson assumption of 8% ARR. Using the mean 
of this posterior distribution, the resulting incremental cost per QALY exceeded 
$500,000 in 65 year-old men – a value unlikely to be considered cost effective in any 
country. ConClusions: Bayesian analysis allows the prediction of the probability 
that a treatment alternative exceeds a predefined threshold. A powerful feature of 
Bayesian analysis is the ability to incorporate additional and/or newer data. This 
newer data can drastically alter assumptions about the cost effectiveness of treat-
ment alternatives.
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objeCtives: Aortic stenosis is the most common valvular heart disease in the 
elderly –its prevalence is estimated to be up to 5% in individuals over 75 years. 
Surgical replacement of aortic valve is considered the standard care and in the 
absence of serious coexisting conditions, the procedure is associated with low 
operative mortality. However, a significant proportion of patients cannot undergo 
surgery due to high surgical risk associated with advanced age or presence of 
multiple coexisting conditions. Treatment with transcatheter aortic-valve implan-
tation (TAVI) is a therapy with potentially lower peri-procedure risk and has been 
used as a therapeutic option in this group considered inoperable. This study aims 
to develop a cost-effectiveness analysis of TAVI in patients with severe aortic 
stenosis who are not suitable for surgical treatment according to Brazilian Private 
System Perspective. Methods: A Markov model was developed to compare TAVI 
versus standard therapy (drug treatment with or without aortic balloon valvulo-
plasty) with a 5-year time horizon. Outcomes in the model were based on safety 
and effectiveness (as measured by clinical outcomes of chance of successful 
implantation procedure and survival from PARTNER cohort B trial). Resource use 
included early perioperative complications (30 days) and late events. Cost data 
were obtained from Brazilian public lists (CMED/SIMPRO/CBHPM). Results were 
expressed as incremental cost-effectiveness ratio (ICER) per life years gained 
(LYG). Probabilistic sensitivity analysis was performed to confirm robustness of 
results. Results: Compared with standard therapy with or without aortic balloon 
valvuloplasty, use of TAVI improves survival in 0.97 life years with an incremental 
cost of US$43,602, resulting an ICER of US$45,080/LYG. In an alternative scenario 
considering 10-year time horizon, ICER was 27,565/LYG. ConClusions: Use of 
TAVI results in improved survival with a low risk of serious adverse events, and 
demonstrates a cost-effectiveness profile when compared to other technologies 
already incorporated in Brazil.
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objeCtives: In the SHIFT trial, ivabradine administered to chronic heart failure 
(CHF) patients in combination with standard therapy significantly reduced cardio-
vascular death and hospital admission for cardiovascular problems. An economic 
evaluation of ivabradine plus standard care against standard care alone, for the 
management CHF in patients with a baseline heart rate ≥ 75b.p.m. was conducted 
from the Greek third party-payer perspective. Methods: An existing Markov model 
consisting of two health states for CHF NYHA classes I to IV (i.e. alive, dead) was 
adapted to the Greek health care setting. In each one month cycle, patients can 
either remain alive or die, during their life span or 29 months (i.e. within SHIFT 
trial period). Health state utilities were estimated from EQ-5D index scores obtained 
from the SHIFT clinical trial and using appropriate modeling techniques the data 
were extrapolated beyond the trial period. All costing data reflects the year 2013. 
Probabilistic sensitivity analyses (PSA) were conducted. Both cost and outcomes 
were discounted at 3.5% per year. Results: Results for within trial analysis 
revealed that ivabradine had an incremental cost and incremental QALY of € 905 
and 0.05 respectively, leading to an incremental cost per QALY gained of € 16,635/
QALY. Ivabradine was a cost-effective alternative at a willingness to pay thresh-
old of € 36,000 per QALY gained Moreover, the cumulated lifetime analysis showed 
incremental cost of € 2,792 and incremental QALY of 0.28. The ICER for ivabradine 
was calculated to be € 9,986 per QALY gained. The PSA showed that the likelihood 
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objeCtives: The results of many clinical trials demonstrate the benefit of long-
term antiplatelet therapy in reducing the risk of cardio- and cerebrovascular com-
plications. Both acetylsalicylic acid (ASA) and clopidogrel are effective, but have 
potentially serious side effects, and clopidogrel is more expensive than ASA. The 
purpose of the study is to evaluate the pharmacoeconomic acceptance of clopi-
dogrel versus ASA in patients with atherosclerotic vascular disease manifested 
as either recent ischaemic stroke, recent myocardial infarction, or symptomatic 
peripheral arterial disease to prevent non-fatal stroke and death rate according to 
the clinical trial CAPRIE from Ukrainian perspective. Methods: Outcomes of the 
clinical study CAPRIE, modeling “decision tree” and analysis “cost-effectiveness” 
were used. Results: The results of the clinical trial CAPRIE study showed, that 
clopidogrel is more effective versus ASA for reducing the risk of nonfatal stroke: 
absolute risk reduction is -2.7%. Model “decision tree” was built using the probabili-
ties of events (nonfatal stroke and death) from the study CAPRIE. Direct costs were 
calculated taking into account the costs of antiplatelet therapy, of nonfatal stroke 
treatment (drugs, diagnosis, patient’s stay in hospital) and the cost of rehabilita-
tion after stroke. Indirect costs are not taken into account because the patients 
were of retirement age (62.5 years old). As a result of calculations it was found, 
that antiplatelet therapy with clopidogrel is more expensive and more effective (2 
additional lives saved per 1000 patients over 1.91 years) compared with ASA. Due 
to the threshold of society “willingness to pay” per 1 life saved, or 1 QALY, use of 
clopidogrel as antiplatelet agent in patients with cardiovascular disease is economi-
cally profitable for Ukraine. ConClusions: The use of clopidogrel as an antiplatelet 
agent in patients with cardiovascular disease to prevent nonfatal stroke compared 
to the ASA is economically profitable for Ukraine.
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objeCtives: Stroke and its associated disability costs the European Union an esti-
mated € 62 billion per year. Warfarin is the mainstay for stroke prevention in atrial 
fibrillation (AF), but many patients have absolute contraindications to this drug. The 
Watchman device for left atrial appendage closure (LAAC) received CE mark for stroke 
prevention in AF patients with contraindications to warfarin. This analysis sought to 
estimate the cost effectiveness of treating warfarin-ineligible AF patients with LAAC 
as compared to standard aspirin therapy. Methods: A Markov model was developed 
comparing clinical outcomes and total costs between patients treated with LAAC or 
aspirin over 5 and 10 years based largely on clinical outcomes from the Aspirin and 
Plavix Registry (ASAP) and ACTIVE trials. Clinical events included ischemic stroke, 
TIA, systemic embolism, bleeding, and acute myocardial infarction as well as proce-
dure-related events. Germany was chosen as the country of analysis because of its 
unique DRG for the LAAC procedure. Acute costs were taken from German DRGs and 
long-term disability costs were taken from the Berlin Acute Stroke Study. Sensitivity 
analysis was performed on clinical and cost inputs; the model was most sensitive 
to changes in the rate of ischemic stroke. Results: LAAC demonstrated a benefit 
in terms of ischemic strokes and mortality avoided. The cost per ischemic stroke 
avoided was € 91,020 and € 24,722 at 5 and 10 years, respectively. The cost per life year 
gained for LAAC versus aspirin was € 22,694 at 5 years and decreased to € 5,859 at 
10 years. ConClusions: LAAC is a cost-effective alternative to aspirin therapy in 
patients with contraindications to warfarin. Cost offsets achieved with LAAC become 
considerably more pronounced over time. This analysis highlights the importance of 
considering the lifetime costs of stroke prevention in AF, especially as the probability 
of both stroke and bleeding increases with patient age.
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objeCtives: To perform a cost-effectiveness analysis of rivaroxaban (once-daily) in 
the prevention of stroke and systemic embolism of patients with non-valvular atrial 
fibrillation (NVAF) and in patients sub-groups from the perspective of the Italian 
health care system (SSN). Methods: A Markov model was developed with a life-
time timeframe where a hypothetic NVAF patients’ cohort is treated with Vitamin-K 
antagonists (VKAs), antiplatelet drugs (ASA) or no therapy. Patients remain stable 
or progress towards other health states (ischemic or hemorrhagic stroke, myocar-
dial infarction and bleedings) until death. The base case compares rivaroxaban 
with VKAs. In subgroup analyses, rivaroxaban is compared with patients at highest 
unmet medical need: 1. VKA patients with poor INR control, 2. patients under ASA 
or 3. not treated. Clinical data were derived from ROCKET-AF trial or a network 
meta-analysis. Utility data were retrieved from published literature. Health care 
resources consumption was valued using average regional tariffs in Italy. Since 
rivaroxaban price is not officially published, the price of the first novel oral antico-
agulant approved in this indication in Italy was considered. Model outcomes are 
expressed in terms of incremental cost per quality adjusted life year (QALY) gained 
(ICER). Univariate and probabilistic sensitivity analyses were performed Results: 
In the base case, rivaroxaban showed to be cost-effective compared to VKA with an 
VKA-unsuitable, respectively) formed the basis of the analysis. Clinical events 
(ischemic strokes, hemorrhagic strokes, intracranial hemorrhages, other major 
bleeds, clinically relevant non-major bleeds, myocardial infarctions and car-
diovascular hospitalizations) were modeled over a lifetime horizon based on 
the clinical efficacy of each comparator, as reported by two phase-III clini-
cal trials (ARISTOTLE and AVERROES). Resource use with regards to patient 
monitoring was elicited via an experts’ panel (cardiologists & internists). 
Cost calculations reflect the local clinical setting, and followed a third-party 
payer perspective (Euros, year 2013, discounted at 3%). Results: Apixaban 
was projected to reduce the occurrence of clinical events and increase quality 
adjusted life expectancy compared to warfarin and aspirin (an incremental 
increase of 0.225 and 0.274 QALYs per patient, respectively). Taking into account 
costs of medications, treatment and management of events, the incremental 
cost-effectiveness ratio for apixaban versus warfarin and aspirin was esti-
mated at 12,154.6 € /QALY and 5,980.6 € /QALY gained, respectively. Extensive 
sensitivity analyses indicated that results were robust over a wide range of 
inputs. ConClusions: Based on the results of this analysis, apixaban can 
be a cost-effective alternative to warfarin and aspirin for the management of 
VKA-suitable and VKA-unsuitable patients with NVAF, respectively, in Greece.
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objeCtives: Intravascular ultra-sound (IVUS) allows physicians to generate a supe-
rior image of coronary arteries during percutaneous coronary interventions (PCI), 
providing a tomographic, 360-degree view of the arterial wall from the inside, which 
allows a more accurate and complete assessment than is possible with angiography. 
The purpose of this study was to understand the cost-effectiveness of IVUS com-
pared with traditional angiography techniques in drug-eluting stent (DES) implanta-
tion, from the perspective of the Italian health system. Methods: A Markov model 
was developed to extrapolate the comparative costs and outcomes of a theoretical 
population of 1000 patients undergoing DES implantation with traditional angiogra-
phy alone, or in conjunction with IVUS. The model assesses cardiac events, including 
revascularisations and myocardial infarctions from a health system perspective. 
Outcomes with and without IVUS were based on a meta-analysis by Zhang et al 
(2013). Because of limited clinical evidence to inform the long-term outcomes of 
IVUS compared with angiography, the model either assumes the benefit of IVUS 
is conferred only in the first year of treatment, or that the benefit is maintained 
permanently. Results: Using IVUS during PCI cost an average of € 542 per patient, 
and yields an additional 0.022 quality adjusted life years (QALYs) per patient. In a 
population of 1,000 patients, IVUS led to a reduction of 6.7 revascularisations and 
5.9 less myocardial infarctions (MI) over the lifetime of a patient. When the revas-
cularisation and MI benefit of IVUS is assumed to extend for the patient’s lifetime, 
angiography with IVUS costs € 38 per patient and yields an additional 0.09 QALYs 
over a patient’s lifetime; avoiding 13.4 MIs and 12.3 revascularisations per 1,000 
patients. ConClusions: IVUS appears to be a cost-effective addition to traditional 
angiography in DES placement in Italy, with the increased upfront cost of IVUS offset 
by reduced cardiac events in IVUS-treated patients over time.
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objeCtives: Apixaban, dabigatran (150 mg BID and 110 mg BID) and rivaroxaban 
are three novel oral anticoagulants (NOACs) currently approved for stroke preven-
tion and systemic embolism in non-valvular atrial fibrillation (NVAF) patients. 
The objective of this analysis was to assess the cost-effectiveness (CE) of apixa-
ban against other NOACs for the prevention of stroke in patients with NVAF in 
Greece. Methods: A Markov model that evaluated clinical events, quality adjusted 
life expectancy and costs for patients treated with apixaban or other NOACs formed 
the basis of the analysis. Clinical events (ischemic strokes, hemorrhagic strokes, 
intracranial hemorrhages, other major bleeds, clinically relevant non-major bleeds, 
myocardial infarctions and cardiovascular hospitalizations) were modeled for a 
lifetime horizon. Due to lack of head-to-head comparisons, efficacy and safety data 
was derived from an indirect treatment comparison (ITC). The key pivotal trials, 
ARISTOTLE, ROCKET-AF and RE-LY, all included warfarin as a comparator therefore 
allowing for an ITC. Resource use with regards to patient monitoring was elic-
ited via a panel of experts (cardiologists & internists). Cost calculations reflect the 
local clinical setting and followed a third-party payer perspective (Euros, year 2013, 
discounted at 3%). Results: Apixaban was projected to reduce the occurrence of 
clinical events and increase quality-adjusted life expectancy and costs of treatment 
compared to other NOACs. Taking into account costs of medications, treatment 
and management of events, the incremental cost-effectiveness ratios for apixaban 
5 mg BID versus dabigatran 150 mg BID, dabigatran 110 mg BID and rivaroxaban 
20 mg QD were estimated at 15,403€ /QALY, 4,955€ /QALY and 10,130 € /QALY gained, 
respectively. Extensive sensitivity analyses indicated that results were robust over a 
wide range of inputs. ConClusions: Based on the results of this analysis, apixaban 
can be a cost-effective alternative to other NOACs, for the prevention of strokes in 
patients with NVAF in Greece.
